Latest news with #GavinClark-Gartner
Business Insider
15-07-2025
- Business
- Business Insider
Evercore ISI Remains a Hold on Rallybio (RLYB)
Evercore ISI analyst Gavin Clark-Gartner maintained a Hold rating on Rallybio on July 11 and set a price target of $1.00. The company's shares closed today at $0.42. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Clark-Gartner covers the Healthcare sector, focusing on stocks such as Mirum Pharmaceuticals, Sarepta Therapeutics, and ProQR. According to TipRanks, Clark-Gartner has an average return of 5.8% and a 45.07% success rate on recommended stocks. The analyst consensus on Rallybio is currently a Hold rating. The company has a one-year high of $1.54 and a one-year low of $0.22. Currently, Rallybio has an average volume of 2.8M.
Business Insider
12-07-2025
- Business
- Business Insider
Avidity Biosciences price target raised to $70 from $60 at Evercore ISI
Evercore ISI analyst Gavin Clark-Gartner raised the firm's price target on Avidity Biosciences (RNA) to $70 from $60 and keeps an Outperform rating on the shares. The firm adjusted price targets in Smid-cap biotechnology as part of a research note discussing 2026 stock ideas. There is a 'notable lengthening' of time horizons among investors, which is a positive sign for the broader small cap biotech markets, the analyst tells investors in a research note. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Business Insider
12-07-2025
- Business
- Business Insider
Dyne Therapeutics price target lowered to $41 from $46 at Evercore ISI
Evercore ISI analyst Gavin Clark-Gartner lowered the firm's price target on Dyne Therapeutics (DYN) to $41 from $46 and keeps an Outperform rating on the shares. The firm adjusted price targets in Smid-cap biotechnology as part of a research note discussing 2026 stock ideas. There is a 'notable lengthening' of time horizons among investors, which is a positive sign for the broader small cap biotech markets, the analyst tells investors in a research note. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Business Insider
18-06-2025
- Business
- Business Insider
Evercore ISI Remains a Hold on Sarepta Therapeutics (SRPT)
Evercore ISI analyst Gavin Clark-Gartner maintained a Hold rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of $28.00. The company's shares closed today at $21.56. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Clark-Gartner covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Rocket Pharmaceuticals, and Ascendis Pharma. According to TipRanks, Clark-Gartner has an average return of 4.1% and a 45.16% success rate on recommended stocks. In addition to Evercore ISI, Sarepta Therapeutics also received a Hold from Goldman Sachs's Salveen Richter in a report issued today. However, on the same day, TD Cowen maintained a Buy rating on Sarepta Therapeutics (NASDAQ: SRPT).
Business Insider
04-06-2025
- Business
- Business Insider
Rocket Pharmaceuticals (RCKT) was downgraded to a Hold Rating at Evercore ISI
Rocket Pharmaceuticals (RCKT – Research Report) received a Hold rating and a $5.00 price target from Evercore ISI analyst Gavin Clark-Gartner yesterday. The company's shares closed yesterday at $2.96. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Clark-Gartner is a 3-star analyst with an average return of 2.6% and a 41.94% success rate. Clark-Gartner covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Rocket Pharmaceuticals, and Ascendis Pharma. In addition to Evercore ISI, Rocket Pharmaceuticals also received a Hold from Jefferies's Andrew Tsai in a report issued on May 28. However, yesterday, Canaccord Genuity maintained a Buy rating on Rocket Pharmaceuticals (NASDAQ: RCKT). RCKT market cap is currently $298.4M and has a P/E ratio of -1.05. Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RCKT in relation to earlier this year. Last month, Kinnari Patel, the President of RCKT sold 767.00 shares for a total of $4,939.48.
